<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04135521</url>
  </required_header>
  <id_info>
    <org_study_id>108137-E</org_study_id>
    <nct_id>NCT04135521</nct_id>
  </id_info>
  <brief_title>Dose-dense Chemotherapy Versus Intraperitoneal Chemotherapy as First-line Chemotherapy in Advanced Ovarian Cancer</brief_title>
  <official_title>Far Eastern Memorial Hospital</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Far Eastern Memorial Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Far Eastern Memorial Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare dose-dense chemotherapy with intraperitoneal chemotherapy in patients with
      advanced stage ovarian cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Women aged 20 and above, diagnosed with advanced stage ovarian cancer (FIGO stage II~IV), who
      had received debulking surgery, followed by adjuvant chemotherapy (either dose-dense or
      intraperitoneal) at our institution between 01 January 2006 and 31 December 2018 were
      included in the study. Patient characteristics, any treatment related side-effects
      (peri-operative and post-operative complications, chemotherapy related adverse events),
      treatment response (complete or partial response, stable disease or progressive disease),
      post-treatment surveillance (disease status: disease-free, recurrence or cancer-related
      death) will be recorded. Univariate and multivariate logistic regression analysis will be
      employed to evaluate the survival benefit of the two different chemotherapy methods.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 28, 2019</start_date>
  <completion_date type="Actual">March 31, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survivals between this intraveous and intraperitoneal chemotherapy groups</measure>
    <time_frame>10 years</time_frame>
    <description>months</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survivals between this two groups</measure>
    <time_frame>10 years</time_frame>
    <description>months</description>
  </secondary_outcome>
  <enrollment type="Actual">50</enrollment>
  <condition>Advanced Ovarian Cancer</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Intraperitoneal chemotherapy</intervention_name>
    <description>Intraperitoneal or intravenous dose-dense platinum/taxane chemotherapy</description>
    <other_name>Intravenous dose-dense chemotherapy</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All consecutive women, who underwent intravenous dose-dense or intraperitoneal chemotherapy
        as the front-line chemotherapy were reviewed.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Women with FIGO stage II~IV ovarian cancer

          -  At least one cycle of intravenous dose-dense or intraperitoneal chemotherapy had been
             administered as the front-line chemotherapy.

        Exclusion Criteria:

          -  none
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>advanced ovarian cancer woman</gender_description>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital</name>
      <address>
        <city>Banqiao</city>
        <state>New Taipei</state>
        <zip>22050</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 19, 2019</study_first_submitted>
  <study_first_submitted_qc>October 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 22, 2019</study_first_posted>
  <last_update_submitted>June 25, 2020</last_update_submitted>
  <last_update_submitted_qc>June 25, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Far Eastern Memorial Hospital</investigator_affiliation>
    <investigator_full_name>Sheng-Mou Hsiao</investigator_full_name>
    <investigator_title>Chief of Department of Obstetrics &amp; Gynecology, Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ovarian Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ovarian Epithelial</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>October 22, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/21/NCT04135521/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

